Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023)

Denali Therapeutics (DNLI) has disclosed EBIT Margin for 6 consecutive years, with 41.52% as the latest value for Q4 2023.

  • On a quarterly basis, EBIT Margin rose 45797587.0% to 41.52% in Q4 2023 year-over-year; TTM through Sep 2024 was 153.5%, a 25554.0% increase, with the full-year FY2023 number at 59.51%, up 996827.0% from a year prior.
  • EBIT Margin was 41.52% for Q4 2023 at Denali Therapeutics, up from 8981.45% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 3409.66% in Q2 2023 to a low of 458017.39% in Q4 2022.
  • A 5-year average of 40123.49% and a median of 631.34% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -45740111bps in 2022, then skyrocketed 45797587bps in 2023.
  • Denali Therapeutics' EBIT Margin stood at 218.87% in 2019, then tumbled by -498bps to 1308.52% in 2020, then surged by 53bps to 616.28% in 2021, then tumbled by -74220bps to 458017.39% in 2022, then soared by 100bps to 41.52% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's EBIT Margin are 41.52% (Q4 2023), 8981.45% (Q3 2023), and 3409.66% (Q2 2023).